Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News aTyr Pharma Inc ATYR

Healthcare Biotechnology
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause... see more

Recent & Breaking News (NDAQ:ATYR)

aTyr Pharma to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis Pathogenesis and Resolution

GlobeNewswire March 21, 2023

aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies

GlobeNewswire March 20, 2023

aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update

GlobeNewswire March 9, 2023

aTyr Pharma to Present at March Investor Conferences

GlobeNewswire March 8, 2023

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial Results

GlobeNewswire March 2, 2023

aTyr Pharma Announces Phase 2 Study of Efzofitimod in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Following FDA Clearance of IND Application

GlobeNewswire March 1, 2023

aTyr Pharma Announces Pricing of Public Offering of Common Stock

GlobeNewswire February 9, 2023

aTyr Pharma Announces Commencement of Public Offering of Common Stock

GlobeNewswire February 8, 2023

aTyr Pharma Announces Achievement of Development Milestone by Partner Kyorin Pharmaceutical, Co., Ltd.

GlobeNewswire February 6, 2023

aTyr Pharma to Present New Data on the Mechanism of Action of Efzofitimod at the American Thoracic Society 2023 International Conference

GlobeNewswire January 31, 2023

aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis

GlobeNewswire January 19, 2023

European Commission Grants Orphan Drug Designation for aTyr Pharma's Efzofitimod for Treatment of Sarcoidosis

GlobeNewswire January 18, 2023

aTyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase Fragment

GlobeNewswire December 15, 2022

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 18, 2022

aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update

GlobeNewswire November 10, 2022

aTyr Pharma to Present at Upcoming Investor Conferences

GlobeNewswire November 10, 2022

aTyr Pharma Announces Publication of Positive Data from Phase 1b/2a Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal CHEST

GlobeNewswire November 9, 2022

aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2022 Financial Results

GlobeNewswire November 3, 2022

aTyr Pharma to Present at the Jefferies London Healthcare Conference

GlobeNewswire October 25, 2022

aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets

GlobeNewswire October 11, 2022